Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study (VaPE-Tox)
Pulmonary Disease, Chronic Obstructive, E-cigarettes
About this trial
This is an interventional other trial for Pulmonary Disease, Chronic Obstructive focused on measuring E-cigarettes, COPD
Eligibility Criteria
Inclusion Criteria:
- current use of e-cigarettes (>1x/month but <4 days/week)
Exclusion Criteria:
- any chronic medical or major psychiatric problems including current asthma
- self-reported heavy snoring/sleep apnea
- pre-bronchodilator FEV1 or FVC <80% predicted or FEV1/FVC < lower limit of normal
- MRI exclusions (pregnancy, claustrophobia, metal in body, gadolinium allergy, eGFR <60 mL/min/1.73m2)
- MRI scan with contrast within the last 12 months or planned MRI with contrast in the next 6 months
- use of any of the following in the prior 30 days: any conventional cigarettes, marijuana >10 days, any illicit drugs, any medication or inhalers (excluding hormonal contraceptives)
- binge drinking (≥5 alcoholic beverages over 2 hours) over the prior two weeks
- adverse symptomatic response to the study e-cigarette exposure (e.g., palpitations, shortness of breath, chest pain, headache, dizziness)
Sites / Locations
- Columbia University Irving Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
E-cigarette first
Sham first
Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.